KNBIF

Kane Biotech Inc

KNBIF, USA

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate Acne Vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

https://kanebiotech.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-5.76

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

76.55 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-22.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-8,281.30 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.00% of the total shares of Kane Biotech Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.0026

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.